0001181431-13-017273.txt : 20130315 0001181431-13-017273.hdr.sgml : 20130315 20130315182131 ACCESSION NUMBER: 0001181431-13-017273 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130315 FILED AS OF DATE: 20130315 DATE AS OF CHANGE: 20130315 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ZOGENIX, INC. CENTRAL INDEX KEY: 0001375151 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 205300780 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE STREET 2: SUITE 650 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 259-1165 MAIL ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE STREET 2: SUITE 650 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: ZOGENIX INC DATE OF NAME CHANGE: 20060911 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: RHOADS ANN D CENTRAL INDEX KEY: 0001250252 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34962 FILM NUMBER: 13695576 MAIL ADDRESS: STREET 1: 4000 NORTH FIRST STREET CITY: SAN JOSE STATE: CA ZIP: 95134 4 1 rrd374405.xml RHOADS FORM 4 X0306 4 2013-03-15 0 0001375151 ZOGENIX, INC. ZGNX 0001250252 RHOADS ANN D C/O ZOGENIX, INC. 12400 HIGH BLUFF DR., SUITE 650 SAN DIEGO CA 92130 0 1 0 0 EVP, CFO, Treasurer & Sec. Right to buy stock 1.99 2013-03-15 2013-03-15 4 A 0 240000 0 A 2023-03-15 Common Stock 240000 1023000 D Right to buy stock 1.99 2013-03-15 2013-03-15 4 A 0 50000 0 A 2023-03-15 Common Stock 50000 1073000 D The option was granted on March 15, 2013 and vests in a series of forty-eight (48) successive, equal monthly installments beginning on March 15, 2013, subject to the Reporting Person's continued employment with the Company on each vesting date. The option was granted on March 15, 2013 and vests in a series of forty-eight (48) successive, equal monthly installments beginning on March 15, 2013, subject to the Reporting Person's continued employment with the Company on each vesting date. Further, this option does not become exercisable until the Company has implemented the Zohydro ER comprehensive safe use and compliance initiatives, as determined by the Board of Directors. Vickie Reed, Attorney-in-fact 2013-03-15